5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

Journal of Urology

Volumn 161, Issue 4, 1999, Pages 1124-1127

  Malmström, Per Uno ^d   Wijkström, Hans ^d   Lundholm, Carl ^d   Wester, Kenneth ^d   Busch, Christer ^d   Norlén, Bo Johan ^d   Ekman, P ^a   Karlberg, L ^d   Ohlsson, J O ^d   Lindeborg, T ^d   Malmstrom P U ^d   Norming, U ^d   Wijkstrom H ^b   Susskind, S ^d   Sten, J ^d   Lagerkvist, M ^d   Jansson, S ^d   Tveter, K J ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d NONE

Author keywords

BCG vaccine; Bladder neoplasms; Instillation drug; Mitomycin C

Indexed keywords

BCG VACCINE; MITOMYCIN C; PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0032836499     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)61607-0     Document Type: Article

References (17)

1. Pawinski, A., Sylvester, R., Kurth, K. H., Bouffioux, C., van der Meijden, A., Parmar, M. K. and Bijnens, L. A.: Combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol., 156: 1934, 1996.
2. Rintala, E., Jauhianien, K., Alfthan, O., Hansson, E., Juusela, H., Kanerva, K., Korhonen, H., Permi, J., Sotarauta, M., Vaalasti, T., Viitanen, J. and Usenius, R.: Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer. Eur. Urol., 20: 19, 1991.
3. Vegt, P. D., Witjes, J. A., Witjes, W. P. J., Doesburg, W. H., Debruyne, F. M. J. and van de Mejden, A. P. M.: A randomized study of intravesical Mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol., 153: 929, 1995.
4. Krege, S., Giani, G., Meyer, R., Otto, T. and Rubben, H.: A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J. Urol., 156: 962, 1996.
5. Lundholm, C., Norlén, B. J., Ekman, P., Johansson, S., Lagerkvist, M., Lindeborg, T., Olsson, J. O., Tveter, K., Wijkström, H., Westberg, R. and Malmström, P. U.: A randomized prospective study comparing long-term intravesical instillations of mitomycin-c and BCG in patients with superficial bladder carcinoma. J. Urol., 156: 372, 1996.
6. Busch, C., Malmström, P. U., Norlén, B. J., Sällström, J., Brodin, T., Lundblad, A.: A grading system for the immunostaining of A, B and H blood group isoantigens in bladder carcinoma. Anticancer Res., 8: 31, 1987.
7. Malmström, P. U., Vasko, J., Wester, K., Norlen, B. J., Busch, C.: Flow cytometric analysis of DNA content of deparaffinized nuclei in urinary bladder carcinomas. APMIS, 97: 811, 1989.
8. Vasko, J., Malmström, P. U., Wester, K., Busch, C.: Prognostic value of a systematized method for determination of mitotic frequency in bladder cancer assisted by image analysis. J. Urogenital Path., 1: 53, 1991.
9. Herr, H. W., Pinsky, C. M., Whitmore, W. F., Sogani, P. C., Oettgen, H. F., Melamed, M. R.: Experience with Bacillus Calmette-Guerin therapy of superficial bladder tumors. Urology, 25: 19, 1985.
10. Pagano, F., Bassi, P., Milani, C., Meneghini, A., Maruzzi, D., Garbeglio, A.: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32, 1991.
11. Cookson, M. S., Herr, H. W., Zhang, Z. F., Soloway, S., Sogani, P. C., Fair, W. R.: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol., 158: 62, 1997.
12. Lamm, D. L., Crawford, E. D., Blumenstein, B., Crissman, J., deVere White, R., Wolf, M., Lowe, B., Sarosdy, M., Schellhammer, P., Sagalowsky, A., Smith, J., Grossman, H. B., Flannigan, R., Moon, T., Brendeler, C. and Coltman, C.: SWOG 8795: a randomized comparison of bacillus Calmette-Guerin and mitomycin C in stage Ta and T1 transitional cell carcinoma of the bladder. J. Urol., part 2, 149: 282A, abstract 275, 1993.
13. Fair, W., Herr, H. and Reuter, V.: Nuclear overexpression of p53 protein in transitional cell bladder cancer: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
14. Hermann, G. G., Horn, T. and Steven, K.: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival on stage T1 transitional cell bladder cancer. J. Urol., 159: 91, 1998.
15. Lipponen, P. K., Eskelinen, J., Terho, R. and Nordling, S.: Proliferation indices as independent prognostic factors in papillary TA-T1 transitional cell bladder tumours. Brit. J. Urol., 72: 451, 1993.
16. Pages, F., Flam, T. A., Vieillefond, A., Molinie, V., Abeille, X., Lazar, V., Bressac-de Paillerets, B., Mosseri, V., Zerbib, M., Fridman, W. H., Debre, B. and Thiounn, N.: p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J. Urol., 159: 1079, 1998.
17. Battifora, H.: p53 immunohistochemistry: a word of caution. Hum. Path., 25: 435, 1994.